Can mycophenolate mofetil be an effective option in the treatment of vascular Behçet's Syndrome
Keywords:
Behcet's Disease, pharmacological treatmentAbstract
Background/Aim
Behcet’s syndrome (BS) is a type of vasculitis that primarily affects veins and tend to involve pulmonary arteries more often than peripheral arteries or the aorta. Inflammation is a central role in the development of thrombotic events in BS. Given its critical role in etiopathogenesis, the use of immunosuppressive therapy is fundamental to the treatment strategy.
The aim of our study is to report our center's experience with mycophenolate mofetil (MMF) treatment in vascular BS (VBS) patients.
Materials and Methods
The clinical, laboratory and imaging findings of the patients receiving MMF treatment for vascular BS were retrospectively evaluated. It was noted whether MMF treatment was induction or maintenance treatment. Treatment related side effects were noted. On the 12th month, patients were evaluated for the development of new events and being in remission.
Results
Five patients underwent MMF treatment for remission induction, while another five patients received MMF for maintenance. Relapses occurred in 2 out of 5 patients who were administered MMF as induction therapy, resulting in the development of acute deep vein thrombosis. Among the five patients receiving MMF as maintenance treatment, only one exhibited an active vascular event. Additionally, one patient was classified as vascularly active based on a CRP level of 10.3 mg/l.
Conclusion
MMF therapy may be an effective and safe treatment agent that can be preferred as azathioprine and cyclosporine in VBS patients, especially in maintenance therapy. This study is the first investigation into MMF treatment in patients with vascular BS.
References
1. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med. 1999;341(17):1284–91. doi:10.1056/NEJM199910213411707
2. Yurdakul S, Hamuryudan V, Yazici H. Behçet syndrome. Curr Opin Rheumatol. 2004;16(1):38–42. doi:10.1097/00002281-200401000-00008
3. Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease. Ann Rheum Dis. 2004;63(11):1445–9. doi:10.1136/ard.2003.014241
4. Seyahi E. Behçet's disease: how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol. 2016;30(2):279–95. doi:10.1016/j.berh.2016.08.002
5. Seyahi E, Yurdakul S. Behçet's syndrome and thrombosis. Mediterr J Hematol Infect Dis. 2011;3(1):e2011026. doi:10.4084/MJHID.2011.026
6. Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H. Vascular involvement in Behçet's syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford). 2014;53(11):2018–22. doi:10.1093/rheumatology/keu233
7. Araz O, Karaman A, Yilmazel Ucar E, Saglam L, Akgun M. Behçet's disease: different systemic manifestations at different ages. Eurasian J Med. 2020;52(3):304–6. doi:10.5152/eurasianjmed.2019.19107
8. Bettiol A, Alibaz-Oner F, Direskeneli H, et al. Vascular Behçet syndrome: from pathogenesis to treatment. Nat Rev Rheumatol. 2023;19(2):111–26. doi:10.1038/s41584-022-00880-7
9. Emmi G, Becatti M, Bettiol A, Hatemi G, Prisco D, Fiorillo C. Behçet's syndrome as a model of thrombo-inflammation: the role of neutrophils. Front Immunol. 2019;10:1085. doi:10.3389/fimmu.2019.01085
10. Emmi G, Bettiol A, Silvestri E, et al. Vascular Behçet's syndrome: an update. Intern Emerg Med. 2019;14(5):645–52. doi:10.1007/s11739-018-1991-y
11. Emmi G, Silvestri E, Squatrito D, Amedei A, et al. Thrombosis in vasculitis: from pathogenesis to treatment. Thromb J. 2015;13:15. doi:10.1186/s12959-015-0047-z
12. Kobayashi M, Ito M, Nakagawa A, et al. Neutrophil and endothelial cell activation in the vasa vasorum in vasculo-Behçet disease. Histopathology. 2000;36(4):362–71. doi:10.1046/j.1365-2559.2000.00859.x
13. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet's syndrome. Ann Rheum Dis. 2018;77(6):808–18. doi:10.1136/annrheumdis-2018-213225
14. Vansteenkiste J, Van Haecke P, Demedts M. Long-term treatment with cyclosporin A and coumarin in pulmonary thromboembolic Behçet's disease. Monaldi Arch Chest Dis. 1998;53(2):142–3.
15. Vansteenkiste JF, Peene P, Verschakelen JA, van de Woestijne KP. Cyclosporin treatment in rapidly progressive pulmonary thromboembolic Behçet's disease. Thorax. 1990;45(4):295–6. doi:10.1136/thx.45.4.295
16. Alibaz-Oner F, Direskeneli H. Management of vascular Behçet's disease. Int J Rheum Dis. 2019;22(Suppl 1):105–8. doi:10.1111/1756-185X.13298
17. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769–74. doi:10.1002/art.1780400425
18. Shugaiv E, Tüzün E, Mutlu M, Kiyat-Atamer A, Kurtuncu M, Akman-Demir G. Mycophenolate mofetil as a novel immunosuppressant in the treatment of neuro-Behçet's disease with parenchymal involvement: presentation of four cases. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S64–7.
19. Terashita S, Tanaka T, Taneichi H, Adachi Y, Mori M. Mycophenolate mofetil and prednisolone for cerebral sinus venous thrombosis with Behçet's disease. Pediatr Int. 2019;61(9):920–2. doi:10.1111/ped.13943
20. Ucar D, Esatoglu SN, Cerme E, et al. Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis. Rheumatol Int. 2023;43(11):2099–106. doi:10.1007/s00296-023-05420-4
21. International Team for the Revision of the International Criteria for Behçet's Disease (ITR-ICBD). The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47. doi:10.1111/jdv.12107
22. Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82(1):60–76. doi:10.1097/00005792-200301000-00006
23. Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine (Baltimore). 2012;91(1):35–48. doi:10.1097/MD.0b013e318242ff37
24. Cantini F, Salvarani C, Niccoli L, et al. Treatment of thrombophlebitis of Behçet's disease with low dose cyclosporin A. Clin Exp Rheumatol. 1999;17(3):391–2.
25. Graham RM. Cyclosporine: mechanisms of action and toxicity. Cleve Clin J Med. 1994;61(4):308–13. doi:10.3949/ccjm.61.4.308
26. Aksoy A, Yazici A, Omma A, et al. Efficacy of TNFα inhibitors for refractory vascular Behçet's disease: a multicenter observational study of 27 patients and a review of the literature. Int J Rheum Dis. 2020;23(2):256–61. doi:10.1111/1756-185X.13778
27. Hamuryudan V, Seyahi E, Ugurlu S, et al. Pulmonary artery involvement in Behçet’s syndrome: effects of anti-TNF treatment. Semin Arthritis Rheum. 2015;45(3):369–73. doi:10.1016/j.semarthrit.2015.06.008
28. Hatemi G, Tukek NB, Esatoglu SN, et al. Infliximab for vascular involvement in Behçet's syndrome. Clin Immunol. 2023;253:109682. doi:10.1016/j.clim.2023.109682
29. Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behçet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore). 2016;95(24):e3863. doi:10.1097/MD.0000000000003863
30. Saadoun D, Maalouf G, Vieira M, et al. Infliximab versus cyclophosphamide for severe Behçet's syndrome. NEJM Evid. 2024;3(11):EVIDoa2300354. doi:10.1056/EVIDoa2300354
31. Adler YD, Mansmann U, Zouboulis CC. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease. Dermatology. 2001;203(4):322–4. doi:10.1159/000051781
32. Köse O, Simşek I, Pay S. Mycophenolate sodium in the treatment of mucocutaneous Behçet's disease. Int J Dermatol. 2011;50(7):895–6. doi:10.1111/j.1365-4632.2010.04505.x
33. Greco A, De Virgilio A, Ralli M, et al. Behçet's disease: new insights into pathophysiology, clinical features and treatment options. Autoimmun Rev. 2018;17(6):567–75. doi:10.1016/j.autrev.2017.12.006
34. Furst DE. Leflunomide, mycophenolic acid and matrix metalloproteinase inhibitors. Rheumatology (Oxford). 1999;38(Suppl 2):14–8. PMID: 10646484.
Downloads
How to Cite
Issue
Section
License
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
